The recent finalization of plans for a sprawling manufacturing facility in North Carolina signals a monumental shift in how the pharmaceutical industry approaches the delivery of critical healthcare within the borders of the United States. This development follows a massive $23 billion initiative
The Hook A single campus rising on Chengdu’s industrial edge promised to compress plasmid-to-IND timelines, scale from 15 L to 15,000 L without a tech dead end, and finish products on a dual‑chamber lyophilization line co‑established with a commercial partner—an audacious bet that turned heads
The invisible thread connecting the price of a barrel of crude oil in the Middle East to the cost of a child's plush toy in a local department store is much shorter than most consumers realize. While gasoline prices often dominate the evening news cycles during periods of geopolitical instability,
The United States is currently navigating a fundamental reorganization of its pharmaceutical security as the federal government moves to detach the nation from its long-standing dependence on international manufacturing hubs for essential medications. This strategic shift is crystallized in the
The shift in the global biopharmaceutical manufacturing map has moved toward the Asia-Pacific region as developers seek diversified supply chains and cutting-edge production capacity. AGC Biologics has anchored its presence in this shifting landscape with a $350 million expansion in Yokohama, a
The landscape of modern oncology is currently undergoing a radical transformation as the pharmaceutical industry moves away from broad-spectrum treatments toward the surgical precision of nuclear medicine. While traditional therapies often struggle with systemic toxicity, radioligand therapy (RLT)
